Silencing of PRR11 suppresses cell proliferation and induces autophagy in NSCLC cells

Publication date: June 2018Source: Genes &Diseases, Volume 5, Issue 2Author(s): Lian Zhang, Yunlong Lei, Ying Zhang, Yi Li, Youquan Bu, Fangzhou Song, Chundong ZhangAbstractOur previous studies have demonstrated that proline-rich protein 11 (PRR11) is a novel tumor-related gene and implicates in regulating the proliferation in lung cancer. However, its precise role in cell cycle progression remains unclear. Our recent evidences show that PRR11 silencing has an effect on autophagy in non-small-cell lung cancer (NSCLC) cells. Two human NSCLC cell lines, H1299 and A549 were transiently transfected with against PRR11 siRNA. The Cell Counting Kit-8 and plate clone formation assay showed that downregulation of PRR11 inhibited the cell proliferation associated with cell cycle related genes reduced. And our data suggested that PRR11 depletion expression enhanced the autophagosomes formation, followed with downregulation of P62 and upregulation of LC3-II protein. Furthermore, the immunoblotting results indicated that silencing of PRR11 inactivated the Akt/mTOR signaling pathway. Collectively, these results demonstrated PRR11 had an effective role in autophagy in NSCLC cells through Akt/mTOR autophagy signaling pathways. Therefore, it is helpful to clarify the function of PRR11 in tumorigenesis of NSCLC.
Source: Genes and Diseases - Category: Genetics & Stem Cells Source Type: research

Related Links:

In lung cancer, several potential mechanisms of intrinsic and acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been explored, including mesenchymal-epithelial transition factor (MET) signaling pathway activation. On the other hand, vascular endothelial growth factor (VEGF) production of EGFR-mutated lung cancer cells is stimulated by predominantly activated MET signaling pathway. Therefore, the inhibition of VEGF axis as the downstream target of MET signaling pathway seems promising. Here, for the first time, we report the potential efficacy of combination therapy with b...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Zyxin is a crucial ingredient of the cellular mechanotransducing system and can modulate the gene expression. Given its clinical relevance, zyxin is also a promising target for the diagnosis and treatment of certain diseases. Understanding the role of zyxin in force sensing and gene expression regulating provides a compelling challenge for future biomechanics studies, and offers attractive evidence for zyxin as a potential diagnostic marker and therapeutic target for clinical diseases. PMID: 30657586 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Authors: Yang J, Gong W Abstract INTRODUCTION: Approximately 3-5% of patients with non-small cell lung cancer ´╝łNSCLC´╝ëbelonged to anaplastic lymphoma kinase (ALK)-positive NSCLC. The treatment drugs of ALK-positive NSCLC mainly included crizotinib, ceritinib, alectinib and brigatinib. Although these drugs had some effects, most of them were usually easy to develop drug resistance. Lorlatinib is a new inhibitor of ALK for treating ALK-positive NSCLC,the effect is obvious, and not easy to develop resistance. Areas covered: The main mechanism of action, pharmacokinetics, clinical efficacy and safety of lorlatinib w...
Source: Expert Review of Clinical Pharmacology - Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research
This study aimed to investigate the effects of metastasis-associated 1 (MTA1) gene expression and gene silencing in human non-small cell lung cancer (NSCLC) cells in vitro and on angiogenesis in tumor xenografts in vivo in nude mice. MATERIAL AND METHODS Human H460 and H1299 NSCLC cell lines underwent transfection with lentiviral transfer plasmids (lenti) and short-interfering RNA (si-RNA) and included a control group, a lenti-MTA1 group, a lenti-si-MTA1 group, a lenti control group, and a si-RNA control group. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to detect MTA1 gene expression af...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Abstract The elderly are the majority of patients with non-small cell lung cancer (NSCLC). Compared to the overall population's predictive guidance, an effective predictive guidance for elderly patients can better guide patients' postoperative treatment and improve overall survival (OS) and disease-free survival (DFS). Recently, the long non-coding RNAs (lncRNAs) have been found to play an important role in predicting tumor prognosis. To identify potential lncRNAs to predict survival in elderly patients with NSCLC, in the present study, we chose 456 elderly patients with NSCLC and analyzed differentially expressed...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
This study aims to clarify the prognostic role of epidermal growth factor receptor (EGFR) mutations in plasma of non-small cell lung cancer (NSCLC) for resistance to tyrosine kinase inhibitor (TKI), in correlatio...
Source: Clinical and Translational Medicine - Category: Internal Medicine Authors: Tags: Research Source Type: research
ConclusionsOur results suggest that GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells. Thus, GLRX may represent a therapeutic target for increasing the efficiency of gefitinib treatment.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 18 January 2019Source: Pathology - Research and PracticeAuthor(s): Ming-Jenn Chen, Yao-Chen Wang, De-Wei Wu, Chi-Yi Chen, Huei LeeAbstractSrc homology region 2 (SH2)-containing protein tyrosine phosphatase 2 (SHP2) is ubiquitously expressed in cytoplasmic localization, which in turn confers tumor malignancy and poor prognosis in various human cancers. YAP1 interacts with SHP2 to promote translocation of SHP2 to nucleus, which consequently promotes Wnt target activation. However, the oncogenic role of the nuclear localization of SHP2 in human cancers remains unclear. We hypothesized that n...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: Available online 18 January 2019Source: Pathology - Research and PracticeAuthor(s): Binnari Kim, Yun-jeong Jang, Sujin Park, Jung-Il Lee, Hong Kwan Kim, Joungho HanAbstractBackgroundStudies have shown that 30-50% of non-small cell lung cancer (NSCLC) patients develop brain metastasis (BM). Since BM shortens overall survival and decreases the quality of life, early detection and treatment of BM are vital. While data are available for clinical risk factors of NSCLC with BM, histopathological factors are not well understood. Therefore, we evaluated the histopathological related factors which will help early ...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Conditions:   NSCLC;   EGFR T790M;   FDG-PET Intervention:   Drug: Osimertinib Sponsor:   Martin Schuler, Prof. Dr. med. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Study